S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Sell every Stock except ONE (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
Sell every Stock except ONE (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Sell every Stock except ONE (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
Sell every Stock except ONE (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Sell every Stock except ONE (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
Sell every Stock except ONE (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Sell every Stock except ONE (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
Sell every Stock except ONE (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
NYSE:RDY

Dr. Reddy's Laboratories (RDY) Competitors

$54.50
+0.04 (+0.07%)
(As of 05/26/2023 07:00 PM ET)
Compare
Today's Range
$54.36
$54.97
50-Day Range
$53.34
$61.08
52-Week Range
$49.79
$61.40
Volume
280,400 shs
Average Volume
220,674 shs
Market Capitalization
$9.08 billion
P/E Ratio
16.37
Dividend Yield
0.59%
Price Target
$67.00

RDY vs. TEVA, RXDX, JAZZ, KRTX, APLS, UTHR, ROIV, LEGN, VTRS, and CTLT

Should you be buying Dr. Reddy's Laboratories stock or one of its competitors? The main competitors of Dr. Reddy's Laboratories include Teva Pharmaceutical Industries (TEVA), Prometheus Biosciences (RXDX), Jazz Pharmaceuticals (JAZZ), Karuna Therapeutics (KRTX), Apellis Pharmaceuticals (APLS), United Therapeutics (UTHR), Roivant Sciences (ROIV), Legend Biotech (LEGN), Viatris (VTRS), and Catalent (CTLT). These companies are all part of the "pharmaceutical preparations" industry.

Dr. Reddy's Laboratories vs.

Teva Pharmaceutical Industries (NYSE:TEVA) and Dr. Reddy's Laboratories (NYSE:RDY) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends, community ranking and profitability.

Dr. Reddy's Laboratories has a net margin of 18.38% compared to Teva Pharmaceutical Industries' net margin of -10.73%. Teva Pharmaceutical Industries' return on equity of 27.58% beat Dr. Reddy's Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Teva Pharmaceutical Industries -10.73% 27.58% 5.69%
Dr. Reddy's Laboratories 18.38% 20.90% 14.72%

Dr. Reddy's Laboratories has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$14.93 billion0.55-$2.35 billion-$1.44-5.17
Dr. Reddy's Laboratories$2.99 billion3.03$563.34 million$3.3316.37

Teva Pharmaceutical Industries has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500.

Teva Pharmaceutical Industries received 998 more outperform votes than Dr. Reddy's Laboratories when rated by MarketBeat users. Likewise, 67.59% of users gave Teva Pharmaceutical Industries an outperform vote while only 58.33% of users gave Dr. Reddy's Laboratories an outperform vote.

CompanyUnderperformOutperform
Teva Pharmaceutical IndustriesOutperform Votes
1299
67.59%
Underperform Votes
623
32.41%
Dr. Reddy's LaboratoriesOutperform Votes
301
58.33%
Underperform Votes
215
41.67%

Teva Pharmaceutical Industries currently has a consensus target price of $10.67, indicating a potential upside of 43.18%. Dr. Reddy's Laboratories has a consensus target price of $67.00, indicating a potential upside of 22.94%. Given Teva Pharmaceutical Industries' higher possible upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Dr. Reddy's Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teva Pharmaceutical Industries
3 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.00
Dr. Reddy's Laboratories
2 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Dr. Reddy's Laboratories had 1 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 10 mentions for Dr. Reddy's Laboratories and 9 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 0.30 beat Dr. Reddy's Laboratories' score of 0.02 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Teva Pharmaceutical Industries
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral
Dr. Reddy's Laboratories
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

50.4% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 9.8% of Dr. Reddy's Laboratories shares are held by institutional investors. 0.8% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Teva Pharmaceutical Industries beats Dr. Reddy's Laboratories on 9 of the 17 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RDY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RDY vs. The Competition

MetricDr. Reddy's LaboratoriesPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$9.08B$5.83B$4.48B$14.38B
Dividend Yield0.58%2.71%2.40%4.08%
P/E Ratio16.375.1198.6817.84
Price / Sales3.03346.283,580.898.86
Price / Cash12.8620.3121.9315.14
Price / Book3.144.734.576.91
Net Income$563.34M$187.13M$116.02M$895.50M
7 Day Performance0.68%-3.54%-2.22%-1.51%
1 Month Performance-9.86%1.58%5.77%-1.97%
1 Year Performance-3.21%16.81%20.09%-10.22%

Dr. Reddy's Laboratories Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TEVA
Teva Pharmaceutical Industries
2.1233 of 5 stars
$7.69
-3.3%
$10.75
+39.8%
-17.6%$8.54B$14.93B-5.3436,826
RXDX
Prometheus Biosciences
1.4384 of 5 stars
$198.70
+2.7%
$153.36
-22.8%
+604.3%$9.50B$6.81M-56.4572Gap Up
High Trading Volume
JAZZ
Jazz Pharmaceuticals
2.7673 of 5 stars
$130.38
-1.9%
$200.75
+54.0%
-16.6%$8.34B$3.66B-51.332,800Analyst Revision
KRTX
Karuna Therapeutics
2.2469 of 5 stars
$222.64
-1.4%
$277.13
+24.5%
+104.8%$8.34B$10.64M-23.26118
APLS
Apellis Pharmaceuticals
1.5121 of 5 stars
$86.09
-1.6%
$90.93
+5.6%
+104.1%$10.03B$75.42M-13.73476Short Interest ↑
UTHR
United Therapeutics
3.177 of 5 stars
$216.19
-1.1%
$285.82
+32.2%
-12.1%$10.13B$1.94B14.56965Positive News
ROIV
Roivant Sciences
2.0869 of 5 stars
$9.39
-2.8%
$12.80
+36.3%
+130.4%$7.12B$55.29M-5.28620
LEGN
Legend Biotech
1.72 of 5 stars
$66.54
-3.5%
$78.89
+18.6%
+47.7%$10.98B$117M0.001,390Analyst Revision
VTRS
Viatris
2.8562 of 5 stars
$9.24
-1.2%
$12.67
+37.1%
-25.6%$11.08B$16.26B5.8937,000
CTLT
Catalent
3.1624 of 5 stars
$38.13
+1.7%
$74.30
+94.9%
-64.8%$6.87B$4.83B16.8719,000

Related Companies and Tools

This page (NYSE:RDY) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -